Liquidia (LQDA) Expected to Announce Earnings on Wednesday

Liquidia (NASDAQ:LQDA) is expected to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Liquidia to announce earnings of $0.7580 per share and revenue of $168.48 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The company’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, analysts expect Liquidia to post $3 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Liquidia Stock Up 5.4%

NASDAQ:LQDA opened at $88.38 on Wednesday. The company has a market cap of $7.86 billion, a price-to-earnings ratio of 631.33 and a beta of 0.58. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock’s fifty day moving average price is $74.79 and its two-hundred day moving average price is $52.72. Liquidia has a 52-week low of $19.02 and a 52-week high of $91.10.

Insider Buying and Selling

In other news, Director Stephen M. Bloch sold 100,000 shares of Liquidia stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $89.48, for a total transaction of $8,948,000.00. Following the transaction, the director directly owned 501,477 shares of the company’s stock, valued at $44,872,161.96. This trade represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jason Adair sold 688 shares of the company’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64. Following the completion of the sale, the insider owned 216,438 shares of the company’s stock, valued at approximately $18,944,818.14. This represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 2,175,754 shares of company stock valued at $143,922,108. 25.60% of the stock is owned by company insiders.

Institutional Trading of Liquidia

Several hedge funds have recently bought and sold shares of LQDA. nVerses Capital LLC acquired a new position in shares of Liquidia in the fourth quarter valued at approximately $335,000. Creative Planning raised its holdings in shares of Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after acquiring an additional 7,765 shares during the period. Entropy Technologies LP bought a new stake in Liquidia in the 4th quarter valued at $326,000. Numerai GP LLC bought a new stake in Liquidia in the 3rd quarter valued at $288,000. Finally, Resurgent Financial Advisors LLC acquired a new position in Liquidia in the 4th quarter worth $259,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LQDA has been the topic of several recent research reports. Bank of America reiterated a “neutral” rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Piper Sandler set a $129.00 price target on shares of Liquidia in a research report on Friday, July 24th. Needham & Company LLC increased their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. BTIG Research raised their price objective on shares of Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Finally, Stephens set a $130.00 target price on shares of Liquidia in a research report on Friday, July 24th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and an average price target of $86.18.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).